Press Release

Ref: ADL/SE/2026-27/29 July 31, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sub: Press Release Please find attached herewith press release titled “Aarti Drugs Limited Announces Leadership Transition to Strengthen Governance and Ensure Long-Term Strategic Growth”. Kindly take the same on record. Thanking you, Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932 Aarti Drugs Limited Announces Leadership Transition to Strengthen Governance and Ensure Long-Term Strategic Growth Board approves elevation of Shri Rashesh C. Gogri to Chairman in addition to his existing role as Managing Director and appointment of Shri Adhish P. Patil as Managing Director; Shri Prakash M. Patil to retire as Chairman, Managing Director & CEO, with leadership transition effective October 1, 2026 Mumbai, July 31, 2026: Aarti Drugs Limited (ADL/the Company), one of India’s leading API pharmaceutical companies, today announced key changes to its leadership team. The Board of Directors, at its meeting held on July 31, 2026, approved the elevation of Shri Rashesh C. Gogri to Chairman in addition to his existing role as Managing Director and the appointment of Shri Adhish P. Patil as Managing Director, both effective October 1, 2026. The changes, made on the recommendation of the Nomination and Remuneration Committee, mark the next step in strengthening ADL's leadership bench as the Company builds on its manufacturing scale, R&D capabilities and customer relationships to pursue its next phase of growth. Shri Prakash M. Patil, who has steered the Company as Chairman since 2014 and has been associated with ADL since its inception, will step back from his executive responsibilities as Chairman, Managing Director and Chief Executive Officer with effect from the close of business hours on September 30, 2026. He will continue his association with the Company for the purpose of providing guidance, strategic support and for smooth transition. Shri Rashesh C. Gogri has been associated with the Company as Managing Director since September 2014, having earlier served as Whole-time Director from October 2012. He holds a degree in Production Engineering from Mumbai University and brings more than 27 years of experience in Production, Marketing and Project Implementation in the chemical and pharmaceutical industry. He also serves as Vice-Chairman & Managing Director of Aarti Industries Limited and as Chairman of Aarti Pharmalabs Limited. Shri Adhish P. Patil has been associated with the Company as Chief Financial Officer since April 2014 and has played a pivotal role in the Company’s growth and operational excellence, leading its finance, technical and commercial functions. He holds a Bachelor of Engineering (IT) degree from Mumbai University and an MBA in Finance and Marketing from the University of Florida’s Warrington College of Business Administration, where he graduated as a gold medallist. He has been named to the ‘Top 100 CFOs India 2014’ list and, in 2024, to the ‘Top 20 CFOs in India’ list published by StartupLanes. His appointment as Managing Director is subject to the approval of shareholders at the ensuing Annual General Meeting. Commenting on the leadership changes, Shri Prakash M. Patil, Chairman, Aarti Drugs Limited, said: “It has been the privilege of my professional life to help build Aarti Drugs from its earliest days into the company it is today. I have complete confidence in Rashesh and Adhish, and in the strength of the team we have built together over the years. I look forward to continuing to contribute by providing guidance, strategic support and ensuring smooth transition, while supporting the Company's next phase of growth” Shri Rashesh C. Gogri, Chairman-designate, Aarti Drugs Limited, said: “Aarti Drugs has always stood for scientific rigour, quality and dependability – values I have had the privilege of helping shape over the past decade as Managing Director. As Chairman, I look forward to build on this foundation, deepen our capabilities across our API and formulations businesses, and pursue the opportunities ahead of us with the same discipline that has always defined this Company.” Shri Adhish P. Patil, Managing Director-designate, Aarti Drugs Limited, said: “I am honoured by the Board's confidence in me. Having spent over a decade with Aarti Drugs across finance and operations, I have seen first-hand the strength of our people, our manufacturing capabilities and our customer as well as other stakeholder relationships. I look forward to working with the entire team to sharpen our execution, deepen our competitiveness and create lasting value for all our stakeholders.” The leadership transition does not alter the Company’s long-term strategic direction. This realignment is aimed to create a natural evolution of ADL's governance framework – one that balances continuity with renewal. By elevating leaders who have grown within the organisation, the Company preserves deep institutional knowledge, technical expertise and long-standing customer relationships, while positioning itself to act with greater speed and clarity across manufacturing, R&D and commercial functions. The change reflects a well-structured approach to succession planning and long-term value creation, ensuring that experienced stewardship and fresh strategic thinking work in tandem as Aarti Drugs scales its operations. About Aarti Drugs Limited Aarti Drugs Limited was established in the year 1984 and forms part of $6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and produces Formulations with its wholly-owned subsidiary-Pinnacle Life Science Private Limited. The Company have total 14 manufacturing facilities out of which 10 manufacturing facilities are in Maharashtra, 3 Manufacturing facilities in Gujarat and 1 Manufacturing facility of Pinnacle is located at Himachal Pradesh. Products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc. For more information, please visit http://www.aartidrugs.com/ Safe Harbor Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors. For more information, please contact Company: Investor Relations (IR) Aarti Drugs Limited Strategic Growth Advisors Pvt. Ltd. CIN: L37060MH1984PLC055433 CIN: U74140MH2010PTC204285 Mr. Rushikesh Deole Mr. Deven Dhruva / Ms. Krisha Shrimankar investorrelations@aartidrugs.com deven.dhruva@sgapl.net / krisha.shrimankar@sgapl.net +91 22 24048199 +91 98333 73300 / +91 87797 99281 http://www.aarti [Showing first 8,000 characters — download PDF for full document]